Rifkin H
Department of Medicine, Montefiore Medical Center, Bronx, New York.
Am J Med. 1991 Jun 24;90(6A):3S-7S. doi: 10.1016/0002-9343(91)90411-p.
Non-insulin-dependent diabetes mellitus (NIDDM) is a major cause of morbidity and mortality worldwide, with a prevalence of 3-7% in most Western countries. Decreased insulin secretion and diminished tissue insulin sensitivity are both implicated in the pathogenesis of the disease; both may be exacerbated by persistent hyperglycemia and improved by normalization of blood sugar levels. Measures to control hyperglycemia, hypertension, and hyperlipidemia are important in the management of NIDDM and prevention of its long-term complications. The effects of dietary modification, exercise, and antihypertensive and antiplatelet therapy, as well as of pharmacologic control of blood sugar, on the vascular and renal complications of NIDDM have been investigated. Gliclazide is a second-generation sulfonylurea drug whose efficacy in the treatment of NIDDM, alone or in combination with insulin, has been widely demonstrated. Studies of the use of gliclazide, reported at recent symposia, are summarized in this review.
非胰岛素依赖型糖尿病（NIDDM）是全球发病和死亡的主要原因，在大多数西方国家的患病率为3%至7%。胰岛素分泌减少和组织胰岛素敏感性降低均与该疾病的发病机制有关；两者都可能因持续高血糖而加剧，通过血糖水平正常化而改善。控制高血糖、高血压和高脂血症的措施在NIDDM的管理及其长期并发症的预防中很重要。已经研究了饮食调整、运动、抗高血压和抗血小板治疗以及血糖的药物控制对NIDDM血管和肾脏并发症的影响。格列齐特是一种第二代磺脲类药物，其单独或与胰岛素联合治疗NIDDM的疗效已得到广泛证实。本次综述总结了近期研讨会上报告的格列齐特使用研究。
